Development of Motavizumab, an Ultra-potent Antibody for the Prevention of Respiratory Syncytial Virus Infection in the Upper and Lower Respiratory Tract

This publication has 23 references indexed in Scilit:

• Ultra-potent Antibodies Against Respiratory Syncytial Virus: Effects of Binding Kinetics and Binding Valence on Viral Neutralization
  Journal of Molecular Biology, 2005
• Tailor-made antibody therapeutics
  Methods, 2005
• Safety and Pharmacokinetics of Palivizumab Therapy in Children Hospitalized with Respiratory Syncytial Virus Infection
  The Pediatric Infectious Disease Journal, 2004
• Neutralizing Anti-F Glycoprotein and Anti-Substance P Antibody Treatment Effectively Reduces Infection and Inflammation Associated with Respiratory Syncytial Virus Infection
  Journal of Virology, 2002
• Comparison of Corticosteroids for Treatment of Respiratory Syncytial Virus Bronchiolitis and Pneumonia in Cotton Rats
  Antimicrobial Agents and Chemotherapy, 2002
• Treatment of Respiratory Syncytial Virus Bronchiolitis and Pneumonia in a Cotton Rat Model with Systemically Administered Monoclonal Antibody (Palivizumab) and Glucocorticosteroid
  The Journal of Infectious Diseases, 2000
• Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk Infants
  Pediatrics, 1998
• Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia
  The Pediatric Infectious Disease Journal, 1998
• Respiratory infections: Their role in airway responsiveness and the pathogenesis of asthma
  Journal of Allergy and Clinical Immunology, 1990
• Aerosolized Ribavirin Treatment of Infants with Respiratory Syncytial Viral Infection
  New England Journal of Medicine, 1983